These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7611253)

  • 1. Erythropoietin in diabetic macular edema and renal insufficiency.
    Friedman EA; Brown CD; Berman DH
    Am J Kidney Dis; 1995 Jul; 26(1):202-8. PubMed ID: 7611253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin.
    Berman DH; Friedman EA
    Retina; 1994; 14(1):1-5. PubMed ID: 8016453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit.
    Brown CD; Kieran M; Thomas LL; Zhao ZH; Larsen R; Friedman EA
    Nephron; 1991; 59(3):394-8. PubMed ID: 1758527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 6. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease.
    Friedman EA; L'Esperance FA; Brown CD; Berman DH
    Kidney Int Suppl; 2003 Nov; (87):S57-63. PubMed ID: 14531775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of reduced red blood cell deformability and diabetic nephropathy.
    Brown CD; Ghali HS; Zhao Z; Thomas LL; Friedman EA
    Kidney Int; 2005 Jan; 67(1):295-300. PubMed ID: 15610255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.
    Schaefer RM; Leschke M; Strauer BE; Heidland A
    Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients.
    Vaziri ND; Ritchie C; Brown P; Kaupke J; Atkins K; Barker S; Hyatt J
    ASAIO Trans; 1989; 35(3):505-8. PubMed ID: 2597519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of recombinant human erythropoietin on renal function in humans.
    Lim VS; Fangman J; Flanigan MJ; DeGowin RL; Abels RT
    Kidney Int; 1990 Jan; 37(1):131-6. PubMed ID: 2299799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Am J Med Sci; 2007 Oct; 334(4):260-4. PubMed ID: 18030182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.
    Lim VS; DeGowin RL; Zavala D; Kirchner PT; Abels R; Perry P; Fangman J
    Ann Intern Med; 1989 Jan; 110(2):108-14. PubMed ID: 2909202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.
    Bosman DR; Winkler AS; Marsden JT; Macdougall IC; Watkins PJ
    Diabetes Care; 2001 Mar; 24(3):495-9. PubMed ID: 11289474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.